← Eichor
Study identifier: NCT07054398 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Assessment of Serum Catestatin Level in Acne Vulgaris Patients

Condition: Acne Vulgaris  ·  Sponsor: Aswan University

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to 40 Years
Healthy volunteersYes

About this study

Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults. Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.

This description comes directly from the study's public registry record.

Talk to the study team

Mona Zakaria Mohamed, MSc  ·  +201142550119  ·  mona1704213@aswu.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Aswan Unuversity HospitalAswān, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07054398